FDA Gives Full Approval to Pfizer COVID-19 Vaccine

The mRNA technology that formed the basis of the vaccine provides support to Pfizer's established wide moat and also contributes to BioNTech's positive moat trend.

Karen Andersen, CFA 23 August, 2021 | 12:49PM
Facebook Twitter LinkedIn

Get the Latest Stock Insights in Your Inbox

Subscribe Here

Facebook Twitter LinkedIn

Securities Mentioned in Article

Security NamePriceChange (%)Morningstar Rating
BioNTech SE ADR360.70 USD1.53Rating
Pfizer Inc44.05 USD-1.61Rating

About Author

Karen Andersen, CFA

Karen Andersen, CFA  Karen Andersen, CFA, is a healthcare strategist for Morningstar.

© Copyright 2021 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookies